AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

Cochlear has completed recruitment for two pivotal studies of its investigational fully implantable cochlear implant system. Participants across the broader research program have accumulated more than 1 million hours of experience with the devices, but safety and effectiveness have not been established and the system is not approved for commercial distribution.

Cochlear has completed recruitment for two pivotal studies of its investigational fully implantable cochlear implant system, and participants across the broader program have logged more than 1 million hours of experience with the devices. The milestone advances the company’s research toward planned regulatory submissions, but the system remains investigational: its safety and effectiveness have not been established, and it is not approved for commercial distribution.

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The completed pivotal program comprises the ELEVATE study, conducted at 11 sites in the United States, and the ENTERPRISE study, conducted at five sites in Europe and Australia. Together, the studies enrolled 92 adults. ELEVATE was designed to evaluate the system in 56 adults, while ENTERPRISE was designed for 36. Cochlear said recruitment is complete across the worldwide program; participants will continue to be followed as researchers collect data.

The pivotal studies sit within a longer research effort. Including three earlier feasibility studies dating back to 2005, Cochlear says 117 patients have enrolled across three generations of investigational devices. The company reports more than 1 million hours of patient experience across that full program. That figure describes accumulated device experience; the source does not provide a comparison baseline or break down the hours by study, device generation, or participant.

The pivotal studies plan a primary safety and effectiveness analysis at six months, with follow-up continuing to 12 months. Cochlear said ongoing follow-up and data collection will inform its development program as it moves toward regulatory submissions. The announcement does not report trial results or establish that the device has met safety or performance targets.

At a glance
announcementWhen: Recruitment completion announced; follo…
The developmentCochlear announced that recruitment is complete for its worldwide pivotal trial program, with more than 1 million participant hours recorded across the investigational device program.

Evidence Before a Fully Implantable Device

A fully implantable system could change how some people use cochlear implant technology by placing components beneath the skin, rather than relying on an externally worn sound processor. That design could offer users a different experience in daily activities, but the practical benefit depends on evidence about hearing performance, comfort, safety, and reliability. The more than 1 million hours figure reflects accumulated experience in research; by itself, it does not show how well the system works or how it compares with commercially available devices.

The pivotal studies matter because their safety, effectiveness, and recipient outcome data can help inform a regulatory review. Cochlear says its development priorities include all-day hearing performance and battery longevity, internal dual microphones intended to address body noise, a familiar surgical technique, and confidence grounded in longer-term clinical evidence. These are company-stated priorities, not findings that the studies have already confirmed.

For people considering hearing care now, the distinction between investigational and available treatment is consequential. ELEVATE coordinating investigator Prof Craig Buchman said people who could benefit from a cochlear implant today should not wait for future fully implantable devices. Current cochlear implant technology remains available, while research into this system continues.

Products Worth Considering

Therabody Theragun Sense 2nd Generation Percussion Massage Gun, Black

Therabody Theragun Sense 2nd Generation Percussion Massage Gun, Black

As an affiliate, we earn on qualifying purchases.

Three Device Generations Since 2005

Cochlear’s research program began in 2005 and has studied three generations of investigational devices through feasibility work and, now, two pivotal studies. The current program spans sites in the United States, Europe, and Australia. Its scale reflects a long-running effort to develop a fully implantable option, though the total enrollment and accumulated hours include earlier studies as well as the pivotal trials.

The company says lessons from the program have shaped design priorities around everyday hearing, battery life, internal microphones, surgical workflow, and long-term clinical evidence. ELEVATE and ENTERPRISE are intended to evaluate the investigational system in adults and collect evidence on safety, performance, and recipient outcomes. The announcement provides the studies’ planned enrollment and follow-up schedule, but not detailed protocols, participant characteristics, or outcome data.

Cochlear’s latest commercially available cochlear implant is the Nucleus Nexa System, according to the source report. The fully implantable system discussed in the trials is separate and remains investigational. Any move from research to commercial availability would require regulatory evaluation.

““We now have more than 20 years of experience across three generations of investigational devices.””

— Dig Howitt, Cochlear CEO and president

Trial Outcomes Are Still Pending

The announcement does not give the pivotal studies’ findings on safety, effectiveness, hearing performance, or quality of life. Cochlear says primary analysis is planned at six months and follow-up will continue to 12 months, but it does not state when results will be released or when regulatory submissions will be made. It is also not clear from the report how the more than 1 million hours are distributed among participants, study phases, and device generations.

The system remains unapproved for commercial distribution, and its safety and effectiveness have not been established. The source does not identify a regulator’s review timeline or say whether a submission has been filed. The technology’s potential benefits, including all-day performance and greater freedom in daily listening, remain matters for clinical evaluation rather than confirmed outcomes.

Follow-Up and Regulatory Review

Researchers are expected to continue participant follow-up and data collection through the studies’ planned 12-month period, after the primary analysis at six months. Cochlear says it will use the ongoing work to advance development toward regulatory submissions. Further details about results, submission timing, and any regulatory decisions have not been provided in the announcement.

Until the evidence is reviewed and the system receives any required authorization, the fully implantable device remains a research technology. Buchman said people who may benefit from cochlear implants should discuss currently available options with qualified hearing-care professionals rather than delay care while awaiting this investigational system.

Key Questions

What did Cochlear announce?

Cochlear said recruitment is complete for the ELEVATE and ENTERPRISE pivotal studies of its investigational fully implantable cochlear implant system. It also reported more than 1 million hours of participant experience across the broader research program.

How many people are included in the research program?

The two pivotal studies enrolled 92 adults combined. Including three earlier feasibility studies dating to 2005, Cochlear says 117 patients have enrolled across the full program.

Is the fully implantable system available to patients?

No. The system is investigational and not approved for commercial distribution. Its safety and effectiveness have not been established, and regulatory evaluation is required before it could become commercially available.

When will the studies report results?

The studies plan a primary safety and effectiveness analysis at six months, with follow-up continuing to 12 months. The announcement does not provide dates for public results or regulatory submissions.

Should patients wait for this device before considering a cochlear implant?

ELEVATE investigator Prof Craig Buchman said people who could benefit from a cochlear implant today should not wait for future fully implantable devices. Patients should discuss available options with a qualified hearing-care professional.

Source: rss

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

Scientists Reveal What Sparkling Water Really Does To Your Teeth

New research clarifies how sparkling water affects dental health, revealing both potential risks and safety considerations for consumers.

Semaglutide Linked To Lower Predicted Dementia Risk

New research suggests semaglutide may lower predicted dementia risk, but clinical confirmation is still pending. Findings could impact future treatment approaches.

North-america Blood Culture Tests Market Size, Share,Trends, Growth Analysis Report, 2031

The North American blood culture tests market is projected to grow significantly by 2031, driven by rising infections and technological advances, according to recent report.

Al Manai Launches 4 New Healthcare Projects In Riyadh With 700+ Beds

Al Manai expands its healthcare footprint in Riyadh with four new projects exceeding 700 beds, signaling significant growth in the region’s medical infrastructure.